BLRX Share Price Performance
Recent BLRX News & Updates
No updates
BioLineRx Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0013
- Gross Margin
- 64.90%
- Net Profit Margin
- -15.21%
- Debt/Equity Ratio
- 59.0%
BioLineRx Ltd. Competitors
About BLRX
- Founded
- 2003
- Employees
- 28
- CEO
- WebsiteView website
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Israeli Market Performance
- 7 Days: -1.5%
- 3 Months: 21.3%
- 1 Year: 66.8%
- Year to Date: 28.8%
Over the last 7 days, the market has dropped 1.5%, driven by a decline of 1.9% in the Financials sector. In contrast to the last week, the market is actually up 67% over the past year. Looking forward, earnings are forecast to grow by 16% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading